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a feasibility study
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Abstract
Background: Consultations in primary care for symptoms of urinary tract infections (UTIs) are common and
patients are frequently treated with antibiotics. Given increasing antimicrobial resistance, there has been interest in
non-antibiotic treatment options for common infections. One such option is the use of cranberry extract to treat
symptoms attributable to UTIs.
Methods: A target of 45 women consulting in primary care, with symptoms suggestive of an uncomplicated UTI
for whom the practitioner would normally prescribe antibiotics, will be randomised to receive one of three
treatment approaches: (1) immediate prescription for antibiotics; (2) immediate prescription for antibiotics plus a 7-
day course of cranberry capsules and (3) cranberry capsules plus a delayed prescription for antibiotics to be used in
case their symptoms do not get better, or get worse. Follow-up will be by daily rating of symptoms and recording
of treatments used for 2 weeks in an online symptom diary. Interviews will be conducted with around 10–15 study
participants, as well as with around 10–15 women who have experienced a UTI but have not been approached to
take part in the study. Both groups will be asked about their experience of having a UTI, their thoughts on non-
antibiotic treatments for UTIs and their thoughts on, or experience of, the feasibility trial. The primary objective is to
assess the feasibility of undertaking a full trial in primary care of the effectiveness of cranberry extract to reduce
antibiotic use for symptoms of acute uncomplicated UTI. The secondary objective is to conduct a preliminary
assessment of the extent to which cranberry might reduce antibiotic use and symptom burden.
Discussion: This feasibility study with embedded interviews will inform the planning and sample size calculation of
an adequately powered trial to definitively determine whether cranberry helps to alleviate the symptoms of acute
uncomplicated UTIs in women and whether it can safely reduce antibiotic use.
Trial registration: ISRCTN registry, ID: 10399299. Registered on 24 January 2019.
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Background
Symptoms of uncomplicated urinary tract infection
(UTI) are a frequent presentation in primary care and
are usually treated with antibiotics [1]. Antibiotic pre-
scribing in primary care is associated with increasing
antibiotic resistance (AMR) [2]. Amid concerns that we
are entering a ‘post-antibiotic era’ [3], there has been
growing interest in the use of non-antibiotic treatments
for common, presumed bacterial infections, such as
UTIs, in order to reduce AMR.
Gagyor et al. [4] found that women with acute UTIs
treated with ibuprofen used fewer antibiotics over 28
days compared to women who were treated with fosfo-
mycin (Incidence rate reduction of 66.5% (95% CI 58.8%
to 74.4%, p < 0.001)). However, women treated with ibupro-
fen had a greater symptom burden compared to those
treated with fosfomycin (mean difference in symptom bur-
den between groups 5.3% (95% CI 3.5 to 7%, p < 0.001))
and a non-significant increase in the number of cases of
pyelonephritis (mean difference 1.7% (95% CI − 0.3 to 3.6,
p = 0.12)). Kronenberg et al. [5] similarly found that women
treated with diclofenac for an acute UTI used fewer antibi-
otics within 30 days compared with those treated with nor-
floxacin (risk difference 37% (95% CI 28 to 46%, p < 0.001
for superiority)). However, norfloxacin treatment led to
earlier resolution of symptoms (risk difference in symp-
tom resolution at day of 27% (95% CI 15 to 38%, p <
0.001 for superiority) and fewer cases of pyelonephritis
(risk difference 5 (95% CI 1 to 8, p = 0.031)), compared
with diclofenac. A further study comparing ibuprofen
with pivmecillinam for acute UTI in women [6] found
that more people treated with ibuprofen required sec-
ondary treatment with antibiotics by day 28 (adjusted
risk difference 36% (95% CI 27 to 44%)) and more women
treated with ibuprofen had episodes of pyelonephritis
(adjusted risk difference 4% (95% CI 1 to 8%)). Fewer
people treated with ibuprofen were symptom free by day 4
(adjusted risk difference 35% (90% CI 27 to 43%)).
A placebo-controlled trial assessing the ability of a herbal
remedy, Uva-ursi, with or without advice to take ibuprofen
to reduce antibiotic use for uncomplicated UTI found that
there was no significant improvement in frequency symp-
toms between those taking Uva-ursi and placebo (− 0.06
(95% CI − 0.33 to 0.21; p = 0.661)), nor between those
taking ibuprofen and those not advised to take ibuprofen
(− 0.01 (95% CI − 0.27 to 0.26; p = 0.951)) [7]. Antibiotic
consumption was not significantly reduced with Uva-Ursi
(OR 0.59 (95% CI 0.22 to 1.58; p = 0.293)), but was reduced
with ibuprofen (OR 0.27 (95% CI 0.10 to 0.72; p = 0.009)).
There were no episodes of pyelonephritis.
Another non-antibiotic candidate treatment for un-
complicated UTIs is cranberry preparations (Vaccinium
macrocarpon). Up to 27% of women already use cran-
berry to help treat UTIs, despite the lack of robust trial
evidence for its benefit [1]. The mechanism of action by
which cranberry might treat UTIs is unclear. The active
ingredient may be proanthocyanidins (PAC) with Type
A linkages. PAC with Type A linkages is thought to pre-
vent Escherichia coli (E. coli) from binding to the uroe-
pithelial lining [8], therefore preventing E. coli from
causing and sustaining a UTI. Trials have assessed the
use of cranberry products to prevent recurrent UTIs.
The most recent Cochrane review on the topic found
that cranberry products did not prevent recurrent UTIs
in women any more than placebo or no treatment (RR
0.86, 95% CI 0.71 to 1.04) [9]. However, the reviewers
highlighted a lack of standardisation of the amount of
active ingredient consumed by participants of studies [9]
and noted withdrawals of up to 55%, largely due to
having to consume large volumes of cranberry juice for
prolonged periods on a daily basis [9].
Thus far, few studies have assessed the potential bene-
fit of cranberry in treating symptoms of an acute, un-
complicated UTI, or indeed assessed whether cranberry
might have a synergistic effect when combined with an-
tibiotics [10–12]. It is possible that through preventing
E. coli from binding to the uroepithelial lining, cranberry
may enhance bactericidal effects of urinary antibiotics. If
cranberry extract safely and effectively treats uncompli-
cated UTIs or acts synergistically with antibiotics, this
could substantially help to reduce the overall antibiotic
exposure. A well-designed and adequately powered study
is required to assess this. However, given that we have
not been able to identify adequate published data rele-
vant for planning such a study, we set out to conduct a
feasibility study to facilitate planning such an effective-




To assess the feasibility of undertaking a trial in primary
care of the effectiveness of cranberry extract for symp-
toms of acute uncomplicated UTI.
Secondary objective
Preliminary assessment of the extent to which cranberry
supplementation affects the number of antibiotic courses
consumed for acute uncomplicated UTI, and impact on
symptom burden.
Design and setting
This will be a three armed, open-label, randomised clin-
ical trial to assess the feasibility of conducting a RCT
comparing the effect of immediate antibiotics, immedi-
ate antibiotics and cranberry capsules, and immediate
cranberry capsules with a delayed prescription for anti-
biotics, on antibiotic consumption and symptom
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burden in women with symptoms of acute uncompli-
cated UTI.
Women presenting with symptoms of uncomplicated
UTI to participating general practices in Oxfordshire will
be invited to participate. The feasibility study requires a sin-
gle consultation with a healthcare practitioner/researcher
for each participant, keeping a symptom diary for up to 14
days, and email ± telephone follow-up at day 14.
Eligibility
Participants suitable for inclusion will be women aged
18 years and above who are willing and able to give in-
formed consent for participation in the study. Women
will be eligible if they consult a participating GP practice
with urinary symptoms suggestive of acute, uncompli-
cated lower UTI (namely dysuria, urgency, frequency,
polyuria/nocturia, haematuria and/or suprapubic pain),
which the GP or healthcare practitioner consider should
be treated with an immediate prescription of antibiotics.
Symptom duration should be 6 days or less, and the po-
tential participant must be willing to receive either an
immediate or delayed antibiotic prescription.
Exclusions will be: cranberry allergy; having taken an
antibiotic in the past 7 days; current regular cranberry
product consumption (5 or more days a week); known or
suspected pregnancy; breastfeeding; taking anti-coagulants
(e.g. warfarin) or anti-platelet agents; unable to obtain a
clean-catch/midstream urine sample (e.g. because of incon-
tinence); in-dwelling catheter; receiving end-of-life care/
palliative care; known underlying structural urological ab-
normalities; previous urological surgery; immunosup-
pressed (e.g. active cancer (excluding localised skin cancer);
receiving chemotherapy; taking regular high-dose orally
administered steroids (> 5mg/day), HIV infection); diabetes
mellitus treated with insulin; signs of clinically suspected
upper UTI/pyelonephritis; inability to complete symptom
diary accurately (e.g. dementia or psychosis); already in-
volved in an interventional research study on UTI; unable
to access Internet/email for the next 2 weeks; unable to
decide on the same day that they contacted a primary care
provider whether they would like to participate.
Recruitment and randomisation
We aim to recruit 45 participants from primary care
sites in Oxfordshire (see Fig. 1). As this is a feasibility
study to inform the design and delivery plans for an
adequately powered multi-centre RCT, we believe that a
sample size of approximately 45 will provide sufficient
data to determine whether the current study design
works well. With a sample size of 45, we would be able
to estimate a loss-to-follow-up rate of 20% with a confi-
dence interval of 9.6 to 34.6%. Given that UTI consulta-
tions account for 3% of all GP consultations [13], we
anticipate being able to recruit at least two participants
per month per GP practice. This would equate to 12
participants from one GP practice over 6 months. We
hope to recruit from a minimum of four GP practices.
Fig. 1 Recruitment and randomisation
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Recruitment will be opportunistic; when a member of
the primary care centre team is in contact with a poten-
tial participant who may be suitable for inclusion, the
potential participant will be approached to take part in
the study. This could be in a GP practice or during a
telephone consultation. Eligible participants who are in-
terested in participating in the study will be given a Par-
ticipant Information Leaflet (PIL). The PIL will give full
details of the feasibility study. Participants who are
recruited by telephone will be given a verbal summary
of the key information contained in the PIL. If inter-
ested in participating, the women will be invited to
attend the primary care centre the same day and will
receive a written version of the PIL. Written, in-
formed consent will be obtained by a healthcare pro-
fessional or a suitably qualified/trained person before
any study procedures begin (see Additional files 1
and 2 for the study PIL and Informed Consent Form
(ICF)). Study posters will also be placed in participat-
ing primary care centres to increase potential partici-
pant awareness of the study.
Research Data Capture (REDCap) and Sentry elec-
tronic databases will be used to register participants to
the feasibility study. REDCap is a secure, password-
protected, web-based system, which will be used to store
the electronic Case Report Forms (CRFs)/information
from the symptom diaries. REDCap will store participant
ID numbers, but no participant-identifiable information.
REDCap will incorporate data-entry and validation rules
to reduce data-entry errors, and management functions
to facilitate auditing and data-quality assurance. Sentry
is a secure, password-protected and encrypted database;
this will be used to store participant-identifiable infor-
mation and will have restricted access.
Participants will be randomly assigned to one of the
three groups in the study in a 1:1:1 ratio. The ran-
domisation sequence will be generated by a statisti-
cian based at Nuffield Department for Primary Care
Health Sciences (NDPCHS), Oxford, using computer-
generated block randomisation with variable block
size. The randomisation code will be accessible only
by the study statistician. REDCap software will ran-
domise participants electronically through the click of
a button by the recruiter during participant registra-
tion. Neither the recruiter nor the participant will
know to which group the participant has been ran-
domly allocated in advance of this step.
Study interventions
Participants will be randomly assigned to one of three
groups:
Group 1 – Immediate prescription of first-line
recommended antibiotics alone
Recruiters will advise participants that they will be free
to use additional medicine/symptomatic treatments (apart
from cranberry juice/extract) to control symptoms at their
discretion. This is the ‘control’ arm.
Group 2 – Immediate prescription of first-line
recommended antibiotics with the addition of
cranberry capsules (provided by the research team)
for up to 7 days
The responsible clinician will give participants an anti-
biotic prescription and, in addition, cranberry (Redicran)
capsules containing 60 mg of cranberry extract (Antho-
cran) and 18mg of PAC. Through ex-vivo experimenta-
tion, Howell et al. [14] found that peak urinary anti-
adhesion activity of PAC occurred at 6 h, and standar-
dised the optimal amount of PAC to consume at 36 mg
twice a day. Participants will, therefore, be advised by re-
cruiters to take two cranberry capsules twice a day, 12 h
apart, until they are free of symptoms, but up to a max-
imum of 7 days. Cranberry capsules will be supplied free
of charge by Indena S.p.A; this company will have no
other involvement in the study (the design, data collec-
tion, analysis or interpretation of findings). Indena S.p.A
manufactures the cranberry extract (Anthocran), which
is used by a different company (Oniria S.r.l.) to produce
the cranberry (Redicran) capsules in compliance with
the applicable European Union legislation. These cap-
sules are available on the Italian market.
Participants can use additional medicine/symptomatic
treatments to control symptoms at their discretion. Data
from this arm in an adequately powered study would as-
sess whether cranberry in addition to antibiotics helps to
reduce symptom burden.
Group 3 – Delayed prescription of first-line recom-
mended antibiotics and immediate cranberry capsules
(provided by the study) for up to 7 days
Participants will receive cranberry capsules (Redi-
cran) and will be advised to take two capsules twice
a day, 12 h apart, until they are free of symptoms,
but up to a maximum of 7 days. Participants will
also receive a delayed prescription for the antibiotic
that the healthcare practitioner would ordinarily
have prescribed for immediate use. Participants will
be advised by the responsible clinician to start the
antibiotics if their symptoms worsen or fail to im-
prove after 3–5 days. Participants can use additional
medicine/symptomatic treatments to control symp-
toms at their discretion. Data from this arm in an
adequately powered study would help to determine
whether antibiotic use can be safely reduced through
cranberry consumption.
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If not already done as part of routine clinical care, all
participants will be asked to provide a mid-stream urine
(MSU) sample to be sent to the GP practice’s local la-
boratory for microscopy, culture and sensitivity.
Assessments and follow-up
Participants will be asked to complete an electronic
symptom diary containing three sections over a period
of 2 weeks [7, 15] (see Additional file 3 for the paper
version of the symptom diary).
Section 1 of the symptom diary
On the day of recruitment, participants will be asked to
enter baseline information. This will include document-
ing whether they have a history of UTIs, use of over-the-
counter treatments that have been tried before seeing
the GP for their current UTI symptoms (e.g. paraceta-
mol, ibuprofen or uvacin).
Section 2 of the symptom diary
Participants will rate the severity of their symptoms each
day for up to 2 weeks (depending on the duration of
their symptoms) on a scale of 0–50. This is an adapta-
tion of the 6-point Likert scale developed by Watson
et al. (2001) [16].
0 = Normal/not affected
1–9 = Very little problem
10–19 = Slight problem
20–29 =Moderately bad
30–39 = Bad
40–49 = Very bad
50 = As bad as it could be
Section 2 of the symptom diary will also allow partici-
pants to enter any treatments/medications that they take
each day. Participants will be emailed a link each day to
complete the diary online for that day.
Section 3 of the symptom diary
In the final section of the symptom diary (day 14), par-
ticipants will complete a final set of questions, including
questions on adverse effects suffered as a result of par-
ticipation in the study, how easy/difficult they found it
to complete the electronic diary and how acceptable they
found the study.
Participants will be emailed to remind them to complete
Section 3 of the electronic symptom diary and/or tele-
phoned to encourage completion of the electronic symp-
tom diary and to obtain a minimal dataset if the diary has
not been adequately completed. Participants who complete
the symptom diary will receive a £10 voucher in recognition
of their contribution to the study. Each participant will have
the right to withdraw from the study at any time without
giving a reason. Any data collected from that participant up
until withdrawal will be kept.
Notes’ review at 1 month
Participants’ GP records will be reviewed to record any
attendances to the GP practice, hospital or out-of-hours
facility within 28 days of the baseline assessment that are
believed to be related to the original UTI episode. The
result of the original urine culture will be recorded on
REDCap; a positive growth will be defined as a growth
of an organism greater than 105 CFU/ml. The Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Figure shows the schedule for enrol-




An adverse event (AE) is any untoward medical occur-
rence that does not necessarily have a causal relationship
with the medicinal product administered. Participants
in group 3 of the feasibility study will not receive im-
mediate antibiotics and may, therefore, be at higher
risk of developing an upper UTI. In the event of a par-
ticipant developing upper urinary tract symptoms,
they will be advised (by the consenting clinician and
information in the study pack) to urgently contact a
medical professional. It will be emphasised in study
materials and when training participating clinicians
that a 7-day course (rather than a 3-day course) of an-
tibiotics is required and that the first-line recom-
mended antibiotic may be different to the antibiotic
that the participant has been prescribed. Details of the
symptoms of upper UTI and actions to take should
they develop will be included within the study mate-
rials. All episodes of upper UTI that develop up to 28
days post randomisation will be recorded.
Discontinuation of cranberry capsules will occur if a
participant has an adverse reaction to the capsules, be-
comes pregnant, or develops a concurrent illness that
the Principal Investigator (PI) or Chief Investigator (CI)
feels precludes ongoing study involvement.
AEs will be reported in four ways: (1) Participants may
contact the study team using the contact details con-
tained within the study pack. We will not provide 24-h
cover as this is an open-label, low-risk study, (2) Partici-
pants may record details of AEs within the symptom
diary, (3) AEs may be reported to GP practices and (4)
AEs may be picked up during the participants’ notes’ re-
view at 1 month.
Serious adverse events
A serious adverse event (SAE) is any untoward medical
occurrence that results in death, is life-threatening,
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requires inpatient hospitalisation or prolongation of
existing hospitalisation or results in persistent or signifi-
cant disability/incapacity. Other ‘important medical
events’ may also be considered serious if they jeopardise
the participant or require an intervention to prevent one
of the above consequences. An SAE occurring to a par-
ticipant will be reported to the Research Ethics Commit-
tee (REC) that gave a favourable opinion of the study
where in the opinion of the CI the event was ‘related’
(resulted from administration of any of the research pro-
cedures) and ‘unexpected’ in relation to those proce-
dures. Reports of related and unexpected SAEs will be
submitted within 15 working days of the CI becoming
aware of the event.
We are not aware of any serious/common side effects
that are associated with consuming cranberry (Redicran)
capsules.
Monitoring
The Trial Steering Committee (TSC) will provide overall
supervision for the study. As this is anticipated to be a
low-risk interventional study, there will not be a separate
Data Monitoring Committee (DMC). The TSC will also
assume the role of the DMC in safeguarding the inter-
ests of study participants and monitoring the overall
conduct of the study. The TSC will be kept informed of
substantial protocol amendments.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure showing schedule of procedures
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Direct access will be granted to authorised representa-
tives from the sponsor (University of Oxford) and host
institution (Nuffield Department of Primary Care Health
Sciences, Oxford) for monitoring and/or audit of the
study to ensure compliance with regulations. The Uni-
versity of Oxford will have access to the final study data-
set. Access to the data will be outlined in the relevant
contract. The University of Oxford has a specialist insur-
ance policy in place which would operate in the event of
any participant suffering harm as a result of their in-
volvement in the research.
Qualitative interview methods
We will conduct one-to-one, semi-structured interviews
with women and will recruit them in two ways. First, we
intend to interview approximately 10–15 women who
take part in the feasibility study. Women who consent to
participate in the feasibility study will be asked whether
they would be happy to be contacted by a member of
the research team to take part in the interview study.
Those who are happy to be contacted will be sent the
CUTI interview study PIL with full details of the study, a
reply slip and a freepost envelope (see Additional file 5
for the interview PIL). Second, we intend to interview
approximately 10–15 women who are not participants of
the study and have not been approached to take part in
the study, but have experienced at least one UTI in the
past 12 months. Interviewing this second group of
women will afford us insights into barriers and facilita-
tors to study recruitment for women who may be less
amenable (compared with women who are taking part in
the feasibility study) to trying non-antibiotic treatments
for UTIs. Recruitment of this second group of women
will take place concurrently with recruitment to the
feasibility study; GP practices not involved with the
feasibility study will conduct a search of their patient
electronic records to identify potentially eligible partici-
pants – women aged 18 years and above who have had
at least one UTI in the past 12 months. Where appropri-
ate, they will then send relevant patients a participation
invitation letter (on GP practice headed paper), a PIL, a
reply slip and a freepost envelope.
Another means of recruitment will include advertising
posters in GP practices and word of mouth; advertising
posters will have tear-off slips at the bottom with con-
tact details for the study team. If a potential participant
is interested in taking part, they can directly contact the
study team. An interview study PIL, reply slip and free-
post envelope can then be sent to potentially eligible
participants.
Written informed consent will be obtained by means
of participant-dated signature and dated-signature of the
person who presented and obtained the informed con-
sent (see Additional file 6 for the interview ICF). A
narrative, semi-structured interview guide [17] will be
used to explore the participants’ experience of having a
UTI, their thoughts on non-antibiotic treatments for
UTIs and their thoughts on, or experience of, taking part
in the feasibility study. The final number of interviews
conducted will be determined by achieving data satur-
ation [18]. As this is a small interview study with modest
aims [19] to learn about the experience or perceived ex-
perience of participating in this trial, we anticipate that
we will achieve saturation with a sample of between 20
and 30 participants. We expect that interviews will take
no longer than 1 h, although the duration may vary from
participant to participant.
Data analysis
Objective 1 – Feasibility of undertaking this study in the
primary care setting
Participants’ diary responses will be reviewed to deter-
mine study acceptability and the findings presented
descriptively.
The data in the symptom diaries will be audited at the
end of the study period to assess the quality and com-
pleteness of data capture. This will include review of the
number of paper diaries, if any, that were provided to
participants due to failure of the electronic diaries. The
rate of recruitment of participants will also be assessed
at the end of the study period, and the proportion of
participants lost to follow-up from each arm will be
reported.
Thematic analysis [20] will be used to develop themes
from interview transcripts. The transcripts will be read
several times for familiarity by the qualitative researcher,
allowing immersion in the data. Codes will be generated
based on the data and these will contribute to the gener-
ation of categories and analytic themes describing the
meaning of the data. NVivo software will be used to aid
in coding and organising the data. Data collection and
analysis will take place concurrently, allowing an itera-
tive evolution of the topic guide. This will also allow a
deeper understanding of the emerging insights, which
will inform further interviews.
Objective 2 – Preliminary assessment of the effect of
cranberry on the number of antibiotic courses consumed
and symptom burden
Exploratory calculations only will be attempted on the
data from this feasibility study; we recognise that the
study is not powered for estimates of effects. Neverthe-
less, we will pilot analysis of outcomes using a statistical
package (e.g. Stata).
The proportion of participants consuming a course (or
part thereof) of antibiotics in each group at 2 weeks and
at the end of the follow-up period will be compared
(group 2 compared with group 1, and group 3 compared
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with group 1) using a log binomial regression model.
The treatment effects will be presented as relative risks.
A Poisson regression model will be used to compare the
number of antibiotic courses (or part thereof) consumed
by participants in each group. Linear regression will be
used to compare the symptom burden in each group,
and time to event analysis will be used to analyse the
time to resolution of symptoms rated ‘moderately bad’
or ‘worse’.
Participants’ notes will be reviewed to record any at-
tendances to the GP practice, hospital or out-of-hours
facilities within 28 days of the baseline visit that are be-
lieved to be related to the original UTI episode. The
number of adverse events reported by participants (dir-
ectly reported by participants and through review of
diaries) and clinicians will be assessed, with the chi-
squared test (or Fisher’s exact test if numbers are small)
used to compare the proportion of AEs and SAEs in
each arm of the study (comparison of total (S) AEs in
each arm and proportion of participants with at least
one (S) AE in each arm).
We will calculate the proportion of participants rando-
mised to receive antibiotics alone who record consuming
cranberry products in their completed symptom diary,
with 95% confidence interval.
Discussion
We are aware of an open-label RCT (EudraCT: 2018–
001448-78) that is currently recruiting in Spain and
assessing the non-inferiority of Cysticlean capsules (con-
taining 240 mg PAC per capsule) compared with fosfo-
mycin for the treatment of acute UTIs in women aged
18 to 64 years. To our knowledge, our study will be the
first randomised clinical trial investigating the use of
cranberry extract alone and as an adjunct to antibiotics
in the management of acute UTIs in women. The feasi-
bility study with embedded qualitative interviews will
provide a platform for the conduct of a rigorous, ad-
equately powered trial to determine whether or not
cranberry is an effective treatment and/or adjunct to
antibiotic treatment for acute uncomplicated UTIs.
We have not incorporated a placebo arm in this feasi-
bility study for a number of reasons: this is not a mech-
anistic study; we intend to recruit small numbers of
participants; and the study is not adequately powered for
estimates of effects. However, arm 1 (usual practice –
immediate antibiotics alone) serves as a control arm.
This pragmatic approach is more closely reflective of
day-to-day clinical practice [21]. In line with this prac-
tical approach, we have also not specified the antibiotic
class, dose or duration that the healthcare practitioner
should prescribe, recommending that they give ‘first-line
antibiotics,’ but we recognise that this may vary accord-
ing to participant characteristics and local guidance.
The findings will be disseminated through journal
publication, blog publication and presentation at confer-
ences. We will also provide a summary of the findings to
participating practices.
Trial status
Protocol version: 1.1, 10 June 2019.
The first site opened to recruitment on 1 July 2019.
First participant recruited 11 July 2019. Approximate
completion date 1 January 2020.
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